Table 6.
Predictors for a deterioration of quality of life
| Variable | Type | < 10 points deterioration | ≥ 10 points deterioration | All | P value |
|---|---|---|---|---|---|
| Gender | Female | 67 (34.0%) | 81 (33.6%) | 148 (33.8%) | 0.4399 |
| Male | 123 (62.4%) | 156 (64.7%) | 279 (63.7%) | ||
| Unknown | 7 (3.6%) | 4 (1.7%) | 11 (2.5%) | ||
| ECOG | 0 | 122 (62.6%) | 183 (76.3%) | 305 (70.1%) | 0.0027 |
| 1 | 60 (30.8%) | 52 (21.7%) | 112 (25.7%) | ||
| ≥ 2 | 13 (6.7%) | 5 (2.1%) | 18 (4.1%) | ||
| Prior chemotherapy | No | 113 (57.4%) | 133 (55.2%) | 246 (56.2%) | 0.6483 |
| Yes | 84 (42.6%) | 108 (44.8%) | 192 (43.8%) | ||
| Prior locoregional treatments | No | 118 (59.9%) | 144 (59.8%) | 262 (59.8%) | 0.975 |
| Yes | 79 (40.1%) | 97 (40.2%) | 176 (40.2%) | ||
| Number of TARE treatments | 1 TARE | 168 (85.3%) | 175 (72.6%) | 343 (78.3%) | 0.0014 |
| 2 or more TARE | 29 (14.7%) | 66 (27.4%) | 95 (21.7%) | ||
| Location of liver tumours | Left | 23 (25.0%) | 29 (21.5%) | 52 (22.9%) | 0.5357 |
| Right | 69 (75.0%) | 106 (78.5%) | 175 (77.1%) | ||
| Prophylactic embolization | No | 96 (65.3%) | 140 (70.7%) | 236 (68.4%) | 0.2859 |
| Yes | 51 (34.7%) | 58 (29.3%) | 109 (31.6%) | ||
| Dose methodology | Partition Model | 75 (38.7%) | 125 (52.5%) | 200 (46.3%) | 0.0041 |
| BSA/mBSA | 119 (61.3%) | 113 (47.5%) | 232 (53.7%) |
Analyses were performed using the Wilcoxon rank-sum test if the number of groups is 2 or with the Kruskal–Wallis test (non-parametric alternative to the ANOVA) if the number of groups exceed 2
BSA body surface area, ECOG Eastern Cooperative Oncology Group, mBSA modified body surface area, TARE transarterial radioembolization